Trial · NCT07883577
A Study of RO7821657 in Participants With Solid Tumors
NCT07883577, Phase 1, Not yet recruiting, Hoffmann-La Roche
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of RO7821657 in Participants With Solid Tumors. Trials, record NCT07883577. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07883577
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of RO7821657 in Participants With Solid Tumors
- NCT number
- NCT07883577
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 405 participants, estimated
- Lead sponsor
- Hoffmann-La Roche
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- RO7821657
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1: Incidence and Severity of Adverse Events (AEs) | Up to approximately 27 months | AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Any events of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded based on the American Society for Transplantation and Cellular Therapy (ASTCT) criteria |
| Primary | Part 2: Incidence and Severity of Adverse Events (AEs) | Up to approximately 27 months | AEs will be graded according to NCI CTCAE v5.0. Any events of CRS and ICANS will be graded based on the ASTCT criteria |
| Primary | Part 1A: Nature and Frequency of Dose-limiting Toxicities (DLTs) | From Cycle 1 (C1) Day 1 to the last day in C1 (Cycle 1 = 14-35 days) | |
| Primary | Part 2A: Nature and Frequency of DLTs | From C1 Day 1 to the last day in C1 (Cycle 1 = 14-35 days) | |
| Primary | Parts 1A and 1B: Recommended Phase 2 Dose (RP2D) Range of RO7821657 | Up to approximately 27 months | |
| Primary | Part 2A: RP2D Range of RO7821657 | Up to approximately 27 months | |
| Secondary | Parts 1 and 2: Serum Concentration of RO7821657 | Up to approximately 27 months | |
| Secondary | Parts 1 and 2: Objective Response Rate (ORR) | Up to approximately 27 months | |
| Secondary | Parts 1 and 2: Disease Control Rate (DCR) | Up to approximately 27 months | |
| Secondary | Parts 1 and 2: Duration of Response (DoR) | Up to approximately 27 months |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07883577
GET https://conductscience.org/api/trials/v1/NCT07883577/registered